VIP550 / Vincerx - LARVOL DELTA

Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) - "NE-cleavable linkers show high elastase-dependent potency with IC50 values of αvβ3 conjugates VIP550, VIP280 and VIP1339 in the nanomolar range across several cancer cell lines (786-0, HT29, NCI-H292, and SUM149) reaching similar potency as compared with the respective payloads alone...αvβ3 conjugates VIP280, VIP550 and VIP1339 demonstrated excellent plasma stability and elastase-mediated release of CPT, P-TEFbi and KSPi payloads in rat plasma as well as in buffer at pH7.4....Strong in vivo efficacy was shown with the SMDC VIP550 with a CPT payload in the MX1 TNBC mouse model."

Preclinical • Oncology